Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Connective Tissue Disease-Related Interstitial Lung Disease
NCT05505409Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pirfenidone in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by Qilu Hospital of Shandong University. Started Jun 2022; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NCT05505409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505409.